PASG – passage bio, inc. (US:NASDAQ)
Stock Stats
News
Passage Bio, Inc. (NASDAQ: PASG) is now covered by analysts at Wedbush. They set an "outperform" rating and a $4.00 price target on the stock.
The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development [Yahoo! Finance]
Passage Bio, Inc. (NASDAQ: PASG) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $7.00 price target on the stock.
Passage Bio, Inc. (NASDAQ: PASG) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $13.00 price target on the stock.
Passage Bio Achieves Milestones in Gene Therapy Trials [Yahoo! Finance]
Form 4 Passage BIO, Inc. For: Dec 09 Filed by: ORBIMED ADVISORS LLC
Form 4 Passage BIO, Inc. For: Dec 04 Filed by: ORBIMED ADVISORS LLC
Form 144 Passage BIO, Inc. Filed by: ORBIMED ADVISORS LLC
Form 144 Passage BIO, Inc. Filed by: ORBIMED CAPITAL LLC
Form 4 Passage BIO, Inc. For: Nov 25 Filed by: Nichols Weston
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.